1. Home
  2. CVKD vs ABP Comparison

CVKD vs ABP Comparison

Compare CVKD & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • ABP
  • Stock Information
  • Founded
  • CVKD 2022
  • ABP 2004
  • Country
  • CVKD United States
  • ABP United States
  • Employees
  • CVKD N/A
  • ABP N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • ABP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVKD Health Care
  • ABP Health Care
  • Exchange
  • CVKD Nasdaq
  • ABP Nasdaq
  • Market Cap
  • CVKD 29.5M
  • ABP 17.2M
  • IPO Year
  • CVKD 2023
  • ABP N/A
  • Fundamental
  • Price
  • CVKD $12.64
  • ABP $0.19
  • Analyst Decision
  • CVKD Strong Buy
  • ABP Strong Buy
  • Analyst Count
  • CVKD 1
  • ABP 1
  • Target Price
  • CVKD $32.00
  • ABP $4.00
  • AVG Volume (30 Days)
  • CVKD 24.4K
  • ABP 3.1M
  • Earning Date
  • CVKD 11-06-2025
  • ABP 08-13-2025
  • Dividend Yield
  • CVKD N/A
  • ABP N/A
  • EPS Growth
  • CVKD N/A
  • ABP N/A
  • EPS
  • CVKD N/A
  • ABP N/A
  • Revenue
  • CVKD N/A
  • ABP $183,000.00
  • Revenue This Year
  • CVKD N/A
  • ABP N/A
  • Revenue Next Year
  • CVKD N/A
  • ABP N/A
  • P/E Ratio
  • CVKD N/A
  • ABP N/A
  • Revenue Growth
  • CVKD N/A
  • ABP 154.17
  • 52 Week Low
  • CVKD $8.74
  • ABP $0.15
  • 52 Week High
  • CVKD $22.90
  • ABP $11.19
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 48.59
  • ABP 41.23
  • Support Level
  • CVKD $13.12
  • ABP $0.16
  • Resistance Level
  • CVKD $13.69
  • ABP $0.19
  • Average True Range (ATR)
  • CVKD 0.59
  • ABP 0.02
  • MACD
  • CVKD -0.06
  • ABP -0.00
  • Stochastic Oscillator
  • CVKD 21.08
  • ABP 34.65

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: